CTSO cytosorbents.com: מקדם חוב לטווח ארוך להון

The ratio of long-term debt to equity for Cytosorbents (CTSO) currently holds around 0.00. Cytosorbents generates revenue from the supply of disposable toxin-removal cartridges to intensive care units. Automated production of consumables ensures high margins. Despite the slow pace of approvals in the US, strong patents for sorption columns maintain business stability in Europe.

Cytosorbents (CTSO) is scaling the implementation of blood purification systems through global clinical trials and physician training. This ratio of long-term debt to equity reflects the share of loans with a maturity of more than one year relative to capitalization. The metric measures the level of long-term leverage, allowing for the real-time assessment of debt obligation revaluation risks. An increase in the coefficient signals a potential rise in financial pressure on the asset. A stable indicator confirms the resilience of the business expansion strategy.